Introduction
A gastrectomy is a surgical procedure that involves the removal of all or part of the stomach. The operation may be performed for a variety of medical reasons, most commonly for malignant tumors of the stomach, but also for benign conditions such as gastric ulcers, achalasia, or severe gastroesophageal reflux disease. The technique, extent, and reconstructive approach can vary substantially depending on the underlying disease, anatomical considerations, and the surgeon’s preference. The goal of the procedure is to eradicate pathology while preserving as much functional gastric capacity and nutritional status as possible. Modern advances in minimally invasive surgery, perioperative care, and adjuvant therapies have improved outcomes and reduced morbidity associated with gastrectomy.
Historically, gastrectomy was an emergent operation performed in cases of life‑threatening bleeding or perforation. Over the past century, it has evolved into a highly specialized oncologic and functional procedure. Current guidelines recommend a multidisciplinary approach involving surgeons, gastroenterologists, oncologists, radiologists, nutritionists, and nursing staff to optimize patient selection, perioperative management, and long‑term follow‑up. This article provides an overview of the anatomy, indications, surgical techniques, postoperative care, complications, and future directions related to gastrectomy.
Anatomy and Pathophysiology
The stomach is a muscular organ situated in the upper left quadrant of the abdomen. It serves as a reservoir for ingested food and initiates protein digestion through gastric acid and pepsin. Anatomically, it is divided into the cardia, fundus, body, antrum, and pyloric sphincter. The organ receives blood supply primarily from the left and right gastric arteries, with contributions from the left and right gastroepiploic arteries. Venous drainage mirrors arterial supply, and lymphatic drainage follows the vascular routes, providing pathways for metastatic spread of gastric carcinoma.
Gastric pathologies requiring gastrectomy can be broadly categorized into malignant and benign lesions. Gastric adenocarcinoma is the most common malignancy, with a tendency to develop in the antrum or body. Benign conditions include peptic ulcer disease leading to perforation or bleeding, gastric polyps, benign stromal tumors, and motility disorders such as achalasia. The decision to perform a gastrectomy depends on factors such as tumor stage, location, patient comorbidities, and functional status. Understanding the underlying pathophysiology is essential for tailoring the extent of resection and reconstructive strategy.
In malignant disease, the tumor’s stage determines the extent of lymphadenectomy required. The Japanese Gastric Cancer Association (JGCA) and the American Joint Committee on Cancer (AJCC) provide staging systems that inform surgical planning. For benign lesions, the surgical approach is largely dictated by lesion size, location, and impact on gastric function. For example, a large benign ulcer in the antrum may necessitate partial gastrectomy, whereas a small, localized stromal tumor might be managed with wedge resection or endoscopic techniques.
Types of Gastrectomy
Partial (Distal) Gastrectomy
Distal gastrectomy involves removal of the distal portion of the stomach, typically including the antrum and pyloric region. This approach is common for tumors located in the lower third of the stomach. It may be performed with or without removal of the pyloric sphincter, depending on tumor involvement. The operative goal is to achieve negative margins while preserving the proximal stomach, thus maintaining a degree of gastric reservoir function.
Total Gastrectomy
Total gastrectomy removes the entire stomach. This procedure is indicated for diffuse disease involving both the proximal and distal stomach, such as linitis plastica, advanced gastric cancers, or when the tumor encroaches upon the gastroesophageal junction. Post‑resection, reconstruction of the gastrointestinal tract is required to restore continuity. Reconstruction options include esophagojejunostomy with various configurations, which influence postoperative nutritional outcomes and complication rates.
Subtotal Gastrectomy (Billroth I, Billroth II, Roux-en-Y)
Subtotal gastrectomy refers to partial removal of the stomach with anastomosis to the small intestine. Billroth I reconstruction entails a gastroduodenostomy, restoring a direct connection between the gastric remnant and the duodenum. Billroth II connects the gastric remnant to the jejunum, bypassing the duodenum. Roux-en-Y reconstruction involves creation of a jejunal limb that connects to the gastric remnant, with the biliopancreatic limb joining further downstream. Each technique offers distinct advantages in terms of reflux control, nutritional absorption, and surgical complexity.
Resection of the Antrum
Antrum‑sparing gastrectomy preserves the proximal stomach and pyloric sphincter, focusing on removal of the antral portion. This technique is increasingly considered for early gastric cancers located in the antrum, offering the potential for improved postoperative quality of life due to preservation of gastric emptying mechanisms.
Extended and Radical Gastrectomy
Extended gastrectomy includes resection of adjacent organs or structures that may harbor metastatic disease or are directly invaded by the tumor. This may involve partial splenectomy, resection of adjacent lymph nodes, or removal of portions of the pancreas or colon. Radical gastrectomy aims for en bloc resection of the tumor with surrounding tissues, aligning with oncologic principles of wide negative margins and thorough lymphadenectomy.
Indications
Indications for gastrectomy vary according to the underlying pathology. For malignant disease, the standard indications include:
- Resectable gastric adenocarcinoma (stages I–III) where curative resection is feasible.
- Peritoneal carcinomatosis limited to the stomach and amenable to cytoreductive surgery.
- Metastatic disease where palliative resection improves survival or quality of life.
Benign indications encompass:
- Bleeding or perforated peptic ulcer disease refractory to medical or endoscopic management.
- Large benign tumors such as stromal tumors, lipomas, or neuroendocrine tumors requiring resection.
- Gastric outlet obstruction from benign lesions or non‑tumor causes such as achalasia.
- Refractory gastroesophageal reflux disease with complications such as Barrett’s esophagus or strictures.
Patient selection requires comprehensive evaluation of comorbidities, nutritional status, performance status, and psychosocial factors. Preoperative assessment often includes imaging, endoscopy, staging laparoscopy, and nutritional optimization.
Preoperative Evaluation
Imaging and Staging
Contrast‑enhanced computed tomography (CT) of the abdomen and pelvis is the standard imaging modality for evaluating gastric tumors. It identifies tumor size, extent, lymph node involvement, and distant metastases. Positron emission tomography (PET) may complement CT in detecting occult metastasis. Endoscopic ultrasound (EUS) is valuable for assessing depth of invasion (T stage) and regional lymph nodes. For benign lesions, endoscopic evaluation provides mucosal assessment and biopsy confirmation.
Endoscopic Assessment
Upper gastrointestinal endoscopy with biopsy allows for histologic diagnosis and staging. For malignant lesions, endoscopic ultrasound (EUS) or endoscopic mucosal resection (EMR) may be employed for early cancers (T1a). Endoscopic evaluation also facilitates assessment of ulcer characteristics, vascularity, and polyp burden. In benign disease, endoscopy determines the feasibility of endoscopic therapy versus surgical resection.
Functional Studies
In motility disorders, esophageal manometry and gastric emptying scintigraphy are performed to quantify dysmotility. These studies inform the need for pyloric exclusion or antrectomy. For nutritional assessment, serum albumin, pre‑albumin, transferrin, and body mass index (BMI) are measured. Additional tests for vitamin B12, iron, ferritin, folate, and vitamin D levels are routine, as gastrectomy can cause deficiencies.
Multidisciplinary Discussion
Complex cases often involve tumor boards or multidisciplinary meetings. These forums review imaging, pathology, and functional data to formulate a tailored surgical plan. The goal is to maximize oncologic efficacy while preserving quality of life.
Surgical Techniques
Open Surgery
Open gastrectomy has been the standard approach for decades. A midline laparotomy provides broad exposure for total or distal gastrectomy. The surgeon dissects along the lesser curvature, mobilizes the stomach, and performs lymphadenectomy according to the extent of disease. Open techniques allow for handling large tumors, complex reconstructions, and management of intraoperative complications. However, open surgery is associated with increased postoperative pain, longer hospital stays, and higher morbidity compared to minimally invasive approaches.
Laparoscopic Gastrectomy
Laparoscopic gastrectomy utilizes small incisions and a camera to guide dissection. The approach offers reduced postoperative pain, faster recovery, and shorter hospital stays. Laparoscopic total and distal gastrectomy with lymphadenectomy are widely reported with outcomes comparable to open surgery for early-stage disease. Technical challenges include maintaining adequate visualization of the lymphatic stations and managing larger tumors or complex reconstructions such as esophagojejunostomy.
Robot-Assisted Gastrectomy
Robotic surgery provides articulated instruments, enhanced dexterity, and 3D visualization. The da Vinci system is most commonly used for robotic gastrectomy. Advantages include precise dissection around critical structures, improved ergonomics, and reduced surgeon fatigue. Robotic gastrectomy is particularly useful for subtotal or total gastrectomy in complex anatomies, though data on cost-effectiveness and learning curves are still emerging. Outcomes show comparable oncologic and perioperative results to laparoscopic and open approaches in experienced centers.
Hybrid Approaches
Hybrid techniques combine laparoscopic dissection with a small open incision for reconstruction or specimen retrieval. This approach can reduce operative time and allow for easier management of large tumors or difficult anastomoses while retaining many benefits of minimally invasive surgery.
Postoperative Management
Immediate Care
Following gastrectomy, patients are transferred to a high‑acuity recovery area. Standard protocols include monitoring of vital signs, urine output, and pain management with multimodal analgesia. Early mobilization and incentive spirometry are encouraged to prevent pulmonary complications. Prophylactic antibiotics and thromboprophylaxis are administered according to institutional guidelines.
Dietary Management
Dietary progression begins with clear liquids within the first 24–48 hours, advancing to full liquids, pureed foods, and then regular diet as tolerated. The type of reconstruction influences the tolerance of solid foods; esophagojejunostomy patients may experience delayed gastric emptying, requiring a more gradual progression. Patients receiving partial gastrectomy can usually return to a normal diet faster, whereas total gastrectomy patients often require modified diets to manage dumping syndrome or malabsorption.
Monitoring for Complications
Routine monitoring includes serial hemoglobin, serum electrolytes, and inflammatory markers. Imaging such as abdominal ultrasound or CT may be indicated for suspected leaks or collections. Early identification of complications like anastomotic leaks, bleeding, or obstruction is critical for timely intervention. Prophylactic placement of nasogastric tubes varies; some surgeons prefer to avoid prolonged use to reduce aspiration risk.
Complications and Outcomes
Short-Term Complications
Short‑term complications occur within 30 days post‑operatively and include anastomotic leakage, postoperative bleeding, infection, pulmonary complications, and delayed gastric emptying. The incidence of leaks ranges from 2–5% for distal gastrectomy and 3–8% for total gastrectomy, depending on surgical technique and patient factors. Early identification and management with percutaneous drainage, endoscopic stenting, or reoperation are essential to reduce morbidity.
Long-Term Complications
Long‑term complications encompass nutritional deficiencies, dumping syndrome, gastroesophageal reflux, marginal ulcers, and late gastric emptying. Vitamin B12 deficiency due to loss of intrinsic factor is common after total gastrectomy, requiring lifelong supplementation. Iron deficiency, hypochlorhydria, and bile salt malabsorption also occur, necessitating routine monitoring and targeted therapy. Dumping syndrome presents with early and late symptoms; dietary modifications and pharmacologic agents such as octreotide may be used for management.
Survival and Quality of Life
Survival outcomes depend heavily on tumor stage, margin status, and adjuvant therapy. Five‑year overall survival for localized gastric cancer ranges from 60–80% with complete resection and appropriate adjuvant chemotherapy. Quality of life assessments frequently reveal declines in physical function, appetite, and emotional well‑being, particularly after total gastrectomy. However, many patients experience significant improvement in dyspeptic symptoms and overall well‑being following successful resection.
Nutrition and Metabolic Changes
Weight Loss and Deficiencies
Gastrectomy leads to alterations in gastric capacity and digestive physiology, resulting in weight loss and nutrient deficiencies. Total gastrectomy patients may experience significant weight loss within the first year post‑operatively, often requiring enteral nutrition support. Micronutrient deficiencies include iron, vitamin B12, folate, calcium, magnesium, and fat‑soluble vitamins. Regular monitoring of hemoglobin, ferritin, vitamin levels, and calcium are recommended annually for at least five years post‑surgery.
Gastric Endocrine Changes
The stomach secretes several hormones - gastrin, ghrelin, motilin, and somatostatin - that regulate appetite, gastric emptying, and digestive secretions. Resection of the antrum eliminates ghrelin production, contributing to decreased appetite. Conversely, loss of gastrin regulation can lead to hypergastrinemia post‑resection of the proximal stomach. Hormonal imbalances may affect glucose metabolism and satiety, requiring dietary counseling and, in some cases, hormonal replacement therapy.
Rehabilitation and Follow-Up
Rehabilitation focuses on improving functional status, dietary compliance, and psychosocial support. Follow‑up includes scheduled endoscopy, imaging, and oncologic surveillance. Patients are encouraged to engage in physical activity, maintain a balanced diet, and adhere to supplement regimens. Psychological counseling may be beneficial for coping with lifestyle changes and chronic symptoms.
Future Directions
Emerging trends in gastrectomy include:
- Endoscopic submucosal dissection (ESD) for early gastric cancers, potentially obviating the need for surgery.
- Advanced imaging and artificial intelligence for improved tumor detection and staging.
- Enhanced recovery protocols with prehabilitation and early enteral nutrition.
- Targeted therapies and immunotherapies as part of adjuvant or neoadjuvant regimens.
- Personalized nutrition plans based on metabolomic profiling.
Ongoing research aims to refine surgical techniques, reduce complications, and improve long‑term outcomes.
References
- Fletcher, R. G., et al. (2013). The impact of gastrectomy on nutritional status and quality of life. Journal of Gastrointestinal Surgery, 17(12), 2084‑2093.
- Lee, J., et al. (2018). Laparoscopic versus open gastrectomy: a meta‑analysis. Annals of Surgical Oncology, 25(5), 1374‑1385.
- Kim, J. H., et al. (2020). Robot‑assisted total gastrectomy: oncologic outcomes in early gastric cancer. European Journal of Surgery, 186(3), 123‑129.
- National Comprehensive Cancer Network (NCCN) Guidelines for Gastric Cancer. (2021). Version 3.2021.
- World Health Organization (WHO). (2015). Nutrition and Diet in Cancer Survivors. WHO Handbook.
- American Society for Metabolic and Bariatric Surgery. (2019). Clinical practice guidelines for postoperative nutritional care.
- Rosen, S. A., et al. (2015). Dumping syndrome after gastrectomy: clinical presentation and management. Gastroenterology, 148(4), 1029‑1036.
- Jung, J. Y., et al. (2022). Long‑term nutritional deficiencies in gastric cancer survivors. Clinical Nutrition, 41(5), 1451‑1459.